AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Alteri Wealth LLC

Alteri Wealth LLC raised its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 64.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,450 shares of the company’s stock after acquiring an additional 2,531 shares during the period. Alteri Wealth LLC’s holdings in AstraZeneca were worth $474,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Dynamic Advisor Solutions LLC lifted its stake in shares of AstraZeneca by 58.4% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 13,055 shares of the company’s stock valued at $960,000 after purchasing an additional 4,811 shares during the period. Geode Capital Management LLC lifted its stake in shares of AstraZeneca by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 498,831 shares of the company’s stock valued at $32,683,000 after purchasing an additional 5,384 shares during the period. Brandywine Global Investment Management LLC purchased a new stake in AstraZeneca in the 4th quarter worth $28,071,000. Farther Finance Advisors LLC increased its holdings in AstraZeneca by 13.1% in the 1st quarter. Farther Finance Advisors LLC now owns 6,083 shares of the company’s stock worth $442,000 after acquiring an additional 706 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in AstraZeneca by 1.8% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 311,600 shares of the company’s stock worth $22,903,000 after acquiring an additional 5,557 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on AZN shares. BNP Paribas started coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They issued an “outperform” rating and a $75.00 price target for the company. Berenberg Bank set a $97.00 price target on shares of AstraZeneca in a report on Wednesday, July 9th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, AstraZeneca currently has a consensus rating of “Moderate Buy” and an average price target of $89.00.

AstraZeneca Price Performance

Shares of NASDAQ AZN opened at $72.66 on Monday. AstraZeneca PLC has a one year low of $61.24 and a one year high of $87.68. The firm has a market cap of $225.34 billion, a PE ratio of 29.18, a PEG ratio of 1.34 and a beta of 0.37. The firm has a fifty day moving average of $71.15 and a 200 day moving average of $71.17. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.70 and a current ratio of 0.90.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.14. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The business had revenue of $13.59 billion during the quarter, compared to analyst estimates of $13.71 billion. During the same quarter in the prior year, the firm earned $2.06 earnings per share. The company’s revenue for the quarter was up 7.2% compared to the same quarter last year. As a group, research analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.